To include your compound in the COVID-19 Resource Center, submit it here.

EpimAb raises $74M series B round to accelerate bispecific immuno-oncology pipeline expansion

How EpimAb plans to use $74M series B to accelerate its bispecific pipeline of immuno-oncology candidates

With proof in hand that EpimAb can quickly move bispecific mAbs from concept to the clinic, the Shanghai company intends to use its $74 million series B round to rapidly expand its pipeline of bispecific cancer therapies.

On Wednesday, EpimAb Biotherapeutics Inc. announced the series B round, which was co-led by Chinese

Read the full 515 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE